• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
1AI
Click for more information
8.33% 1.1¢

ALGORAE PHARMACEUTICALS LIMITED - Charts / Financials

Market Cap $18.56M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Algorae Pharmaceuticals Limited, formerly Living Cell Technologies Limited, is an... Algorae Pharmaceuticals Limited, formerly Living Cell Technologies Limited, is an Australia-based pharmaceutical development company. The Company is focused on discovering and developing novel treatments for medical conditions with under met medical needs. Its programs include AlgoraeOS, Dementia and Parkinson’s. Its drug candidates include NTCELL for Parkinson’s disease and the AI-116 combination drug candidate for dementia. AlgoraeOS is a closed-loop platform, leveraging advanced computational tools to generate novel insights in-silico that are being developed to initiate or accelerate therapeutic programs. The AI-116 is a novel combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The NTCELL is an alginate coated capsule product containing clusters of neonatal porcine choroid plexus cells that are injected into the damaged site within the brain to target the treatment of Parkinson’s disease.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 14.40pm 10/05/2024 (20 minute delay) ?
Day
Open 1.2¢   Day High 1.2¢   Day Low 1.1¢
Daily Volume 190328
Bids   Sellers
Number Price Volume   Number Price Volume
7 1.1¢ 3812323   8 1.2¢ 2178050

Directors & Senior Management

Mr. David Richard Hainsworth Executive Chairman of the Board
Mr. Daya Uka Chief Financial Officer
Dr. Belinda Di Bartolo Chief Operating Officer
Dr. James A. Mckenna Chief Scientific Officer
Dr. Carolyn M. Sue Chief Medical Officer
Ms. Maria Clemente Company Secretary
Mr. Bradley John Dilkes Director
Mr. Bradley Roland Latham Non-Executive Director

Data source: Refinitiv

(20min delay)
Last
1.1¢ 		Change
-0.001(8.33%) 		Mkt cap ! $18.56M
Open High Low Value Volume
1.2¢ 1.2¢ 1.1¢ $2.094K 190.3K

Buyers (Bids)

No. Vol. Price($)
7 3812323 1.1¢
 

Sellers (Offers)

Price($) Vol. No.
1.2¢ 2178050 8
View Market Depth
Last trade - 16.10pm 10/05/2024 (20 minute delay) ?
Last
1.1¢ 		  Change
-0.001 ( 0.00 %)
Open High Low Volume
1.1¢ 1.2¢ 1.1¢ 396096
Last updated 14.40pm 10/05/2024 ?

Top Stories

Prominence impresses the market with uranium grading 5,269ppm in Kazakhstan

Prominence Energy has seen shares rise 33% on news of uranium grading up to 5,269ppm from early sampling work in Kazakhstan.
Tamboran is listing on the NYSE, and Wall Street is paying attention If you needed evidence that Tamboran Resources is bullish on the NT's Beetaloo Basin, look no further than its decision to list on the NYSE.
Gold grading beyond 65g/t at Hillgrove gets Larvotto shares airborne Larvotto Resources has discovered gold grading more than 65 grams per tonne at the Hillgrove project in NSW.
Recce breathes better on positive lung infection drug pilot test results Recce Pharmaceuticals Ltd has revealed positive results from its pilot test on synthetic drug Recce 327, which aims to treat lung infections.
Maiden drilling at West Arunta hints at major IOCG system for Rincon Rincon Resources believes that drill core picked up from a maiden program of work at its West Arunta project in Western Australia indicates potential for a major iron oxide copper gold deposit.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.